All In Biotech

Drug Trial Radar · NCT06280703

A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

A Four-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B, Part C, and Part D), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

121

Actual

Start

May 15, 2024

Primary completion

Oct 3, 2026

Study completion Oct 3, 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec. The study will also evaluate the safety and tolerability of LY3938577 and information about any side effects experienced will be collected. The study will be conducted in four parts (A, B, C, and D). Healthy participants in Part A Period 1 will receive a single dose of LY3938577 or a placebo given via intravenous (IV) infusion. In Part A Period 2, participants will receive a single subcutaneous (SC) dose of either LY3938577 or placebo. Participants in Part B with Type 1 Diabetes Mellitus (T1DM) will receive single doses of either LY3938577 or Insulin Degludec given via IV infusion. Participants in Part C with Type 1 Diabetes Mellitus (T1DM) will receive two doses of either LY3938577 or Insulin Degludec administered SC. Participants in Part D with Type 1 Diabetes Mellitus (T1DM) will be evaluated in 2 periods, with Period 1 administered pre-study basal insulin and lispro mealtime insulin to establish insulin needs, and Period 2 administered lispro mealtime insulin and daily doses of LY3938577. The study will last up to approximately 11 weeks for Part A, 10 weeks for Part B, 13 weeks for Part C, and 10 weeks for Part D , including screening period.

Conditions

  • Healthy
  • Type 1 Diabetes Mellitus

Interventions

  • LY3938577Drug

    Administered Intravenously (IV)

  • PlaceboDrug

    Administered Intravenously (IV)

  • Insulin DegludecDrug

    Administered Intravenously (IV)

  • Insulin LisproDrug

    Administered Intravenously (IV)

  • LY3938577Drug

    Administered subcutaneously (SC)

  • PlaceboDrug

    Administered subcutaneously (SC)

  • Insulin DegludecDrug

    Administered SC

  • Basal InsulinDrug

    Administered subcutaneously (SC)

  • Lispro Prandial InsulinDrug

    Administered subcutaneously (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.Time frame: Baseline up to Approximately Week 11
  2. Part B and D: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.Time frame: Baseline up to Week 10
  3. Part A: Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Baseline up to Approximately Week 11
  4. Part B: Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Baseline up to Week 10
  5. Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory ParametersTime frame: Baseline up to Approximately Week 11
  6. Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory ParametersTime frame: Baseline up to Week 10
  7. Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
  8. Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
  9. Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
  10. Part C: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
  11. Part D: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
  12. Part A: PK: Maximum Observed Concentration (Cmax) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
  13. Part B: PK: Maximum Observed Concentration (Cmax) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
  14. Part C: PK: Concentration of LY3938577Time frame: Predose on day 1 up to week 13 post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Profil Institut für Stoffwechselforschung

    Neuss, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.